UCB To Jump-Start Ongoing Lupus Studies For Immunomedics’ Epratuzumab
This article was originally published in The Pink Sheet Daily
Executive Summary
UCB licenses rights to epratuzumab for all autoimmune disease indications for roughly $208 mil. plus royalties.
You may also be interested in...
Clinical Hold Placed on UCB/Immunomedics Lupus Biologic
Immunomedics says manufacturing issue should not derail Phase III trial.
Clinical Hold Placed on UCB/Immunomedics Lupus Biologic
Immunomedics says manufacturing issue should not derail Phase III trial.
May The Schwarz Be With You: UCB Proposes $5.6 Bil. Acquisition
Existing Schwarz deal with Pfizer unaffected by merger that would create a neurology heavyweight.